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In patients with Barrett’s esophagus (BE), stomach acid chronically damages the esophagus, 
resulting in phenotypic and genetic changes in the tissue lining the esophagus. BE often occurs in 
individuals with gastroesophageal reflux disease, in which stomach acid leaks back into the 
esophagus, causing heartburn. Barrett’s esophagus affects about one percent of adults in the United 
States. While progression to esophageal adenocarcinoma (EAC) is less common, the frequency of 
EAC is rapidly increasing. The progression of BE to EAC is characterized by a series of histologic, 
genetic and epigenetic changes in the esophageal epithelium. However, it remains unclear which of 
these events drive progression of BE to more deadly EAC. 
To investigate the possible tumor suppressor role of a cell junction protein in EAC, Drs. Andrew Kaz 
and William Grady and colleagues in the Clinical Research Division report on the methylation, 
expression and role of PKP1 in progression of BE to EAC.PKP1 encodes a desmosomal protein that 
links cadherins to intermediate filaments within the cell. Thus, PKP1 plays a critical role in cell-cell 
adhesive junctions, including those found in normal esophageal epithelium. PKP1 has also been 
implicated as a tumor suppressor in other epithelial cancers. RT-PCR and immunohistochemical 
staining showed significantly reduced expression of PKP1 in primary tissues from patients with BE, 
high-grade dysplasia or EAC relative to normal tissue. A significant increase in the CpG methylation 
of the promoter of PKP1 was also observed in high-grade dysplasia and EAC relative to normal or 
Barrett’s epithelium. Initial loss of PKP1 expression in BE may be due to methylation at other sites in 
the PKP1 locus or non-methylation factors. During the transition of BE to EAC, CpG methylation is 
likely to ‘reinforce’ this decreased expression of PKP1. Finally, siRNA-mediated knock-down 
of PKP1 in two esophageal cell lines that normally express PKP1 resulted in dramatic increases in 
cell motility. 
Thus, factors that down-regulate PKP1 expression, including CpG methylation, contribute to 
disrupted cell-cell adherence and BE progression. Further identification of the initial factors that 
down-regulate PKP1 expression, as well as the molecular mechanisms behind increased motility will 
further our understanding of EAC development. 
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Immunohistochemical staining shows PKP1 localization at cell-cell interfaces of normal squamous 
esophageal tissues (SQ). Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) tissues 
have decreased or no PKP1 expression, and relocalization of PKP1 to the cytoplasm. 
 
